Search results for "Highlights"
COVID-19 guidance released for managing IBD patients, endoscopic procedures
The American Gastroenterological Association released new guidance for clinicians caring for patients with inflammatory bowel disease (IBD) and those performing endoscopic procedures, and two recent studies looked at GI symptoms in patients with COVID-19.
https://gastroenterology.acponline.org/archives/2020/04/24/1.htm
24 Apr 2020
Guidance issued for comanagement of COVID-19 GI, liver manifestations
Two meta-analyses, one of them from the American Gastroenterological Association (AGA), found that GI symptoms and liver abnormalities are not uncommon in patients with COVID-19. The AGA issued a series of best practice statements based on its findings.
https://gastroenterology.acponline.org/archives/2020/05/22/1.htm
22 May 2020
Efficacy, safety of second-line therapies analyzed for two types of IBS
A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
https://gastroenterology.acponline.org/archives/2019/04/26/2.htm
26 Apr 2019
Antidepressants and psychological therapies reduce IBS symptoms, meta-analysis finds
Psychological therapies were effective for irritable bowel syndrome (IBS) when delivered in person, whereas therapy that was self-administered, internet-based, or provided with minimal contact did not yield significant benefit.
https://gastroenterology.acponline.org/archives/2018/09/28/2.htm
28 Sep 2018
Guideline offers recommendations on anticoagulation, thromboses in vascular liver disorders
Among other guidance, the American College of Gastroenterology recommends anticoagulation for all patients without cirrhosis who have acute symptomatic portal vein thrombosis or mesenteric vein thrombosis in the absence of any contraindication.
https://gastroenterology.acponline.org/archives/2020/01/24/1.htm
24 Jan 2020
New guidelines support probiotics for C. difficile prevention, but few other uses
The American Gastroenterological Association recommended that probiotics be used to treat patients with Clostridioides difficile infection, Crohn's disease, ulcerative colitis, or irritable bowel syndrome only in the context of a clinical trial.
https://gastroenterology.acponline.org/archives/2020/06/26/1.htm
26 Jun 2020
Halting one ulcerative colitis treatment after escalating to new drug may be feasible, study finds
Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
https://gastroenterology.acponline.org/archives/2018/11/27/3.htm
27 Nov 2018
Weight loss interventions may improve biomarkers of liver disease in NAFLD
In a meta-analysis of 22 studies in patients with nonalcoholic fatty liver disease (NAFLD), weight loss interventions were associated with improvements in alanine aminotransferase level, liver steatosis, histologic NAFLD activity score, and nonalcoholic steatohepatitis.
https://gastroenterology.acponline.org/archives/2019/07/26/3.htm
26 Jul 2019
PPI prophylaxis didn't affect 90-day mortality rates among ICU patients
Gastrointestinal bleeds were less common among at-risk ICU patients who received IV pantoprazole instead of placebo, but rates of clinically important events were similar overall.
https://gastroenterology.acponline.org/archives/2018/10/26/2.htm
26 Oct 2018
Rates of HDV co-infection may be higher than previously estimated
Patients with chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) co-infection have the most severe form of viral hepatitis and are at much higher risk for cirrhosis and hepatocellular cancer than patients with HBV infection alone.
https://gastroenterology.acponline.org/archives/2018/09/28/3.htm
28 Sep 2018